Linked Life Data

9150898

Source:http://linkedlifedata.com/resource/pubmed/id/9150898

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1997-7-29
pubmed:abstractText
Based on reports of substantial antitumor efficacy of the combination of mitoxantrone (DHAD), 5-fluorouracil (FU) and leucovorin (LV), a clinical trial was performed to attempt augmentation of the dose of DHAD with filgrastim support. The doses and schedules, all intravenous, were DHAD (total dose divided over days 1 and 2), level I, 16 mg/m2; II, 20 mg/m2; III, 24 mg/m2; IV, 32 mg/m2; and LV, 300 mg, followed by FU, 350 mg/m2, on days 1-3. Filgrastim was given at 5 micrograms/kg/day subcutaneously on days 4-13. The planned cycle length was 21 days. Three or 4 patients were to be entered at each dose level and the maximum tolerated dose (MTD) was defined as the dose immediately below that which resulted in 2 patients with dose-limiting toxicity (DLT) in cycle 1. Once an apparent MTD was identified, an additional 6 patients were to be entered. Twenty patients (pts) were entered: level I: 3 pts; II: 3 pts; III: 10 pts: IV: 4 pts. The major toxicity was found to be cumulative thrombocytopenia with platelet counts < or = 20,000/microL occurring after cycle 1 at all levels beyond level I and five pts (25%) were removed from treatment solely because of platelet toxicity. Additional serious toxicities included grade 4 stomatitis in one patient (level IV) and cardiac toxicity in 2 patients with prior doxorubicin exposure. Ten pts had measurable and 8 had evaluable disease, and in 17 pts assessed, 5 (29%) achieved an objective response. The response rates in this study are lower than reported in the literature for the combination of DHAD, 5FU, LV and this may be related to the fact that only 40% of the patients were removed from protocol treatment because of disease progression. On the basis of limited DHAD-dose augmentation, toxicities observed, and modest response rate, the filgrastim-supported DHAD, 5FU, LV regimen as utilized in this study cannot be recommended for further development for treatment of women with metastatic breast cancer.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0167-6806
pubmed:author
pubmed:issnType
Print
pubmed:volume
43
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
193-200
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:9150898-Adult, pubmed-meshheading:9150898-Aged, pubmed-meshheading:9150898-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:9150898-Breast Neoplasms, pubmed-meshheading:9150898-Dose-Response Relationship, Drug, pubmed-meshheading:9150898-Drug Administration Schedule, pubmed-meshheading:9150898-Female, pubmed-meshheading:9150898-Fluorouracil, pubmed-meshheading:9150898-Granulocyte Colony-Stimulating Factor, pubmed-meshheading:9150898-Humans, pubmed-meshheading:9150898-Leucovorin, pubmed-meshheading:9150898-Leukopenia, pubmed-meshheading:9150898-Middle Aged, pubmed-meshheading:9150898-Mitoxantrone, pubmed-meshheading:9150898-Neoplasm Metastasis, pubmed-meshheading:9150898-Patient Selection, pubmed-meshheading:9150898-Platelet Count, pubmed-meshheading:9150898-Recombinant Proteins, pubmed-meshheading:9150898-Survival Rate, pubmed-meshheading:9150898-Thrombocytopenia, pubmed-meshheading:9150898-Time Factors
pubmed:year
1997
pubmed:articleTitle
Mitoxantrone dose augmentation utilizing filgrastim support in combination with fixed-dose 5-fluorouracil and leucovorin in women with metastatic breast cancer.
pubmed:affiliation
Mayo Clinic, Rochester, MN 55905, USA.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S.